| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 71 |
| 1 | CARBOPLATIN | 35 |
| 2 | IPILIMUMAB | 33 |
| 3 | PEMETREXED DISODIUM | 29 |
| 4 | DURVALUMAB | 19 |
| 5 | METHYLPREDNISOLONE | 10 |
| 6 | PACLITAXEL | 10 |
| 7 | INFLIXIMAB | 9 |
| 8 | ONDANSETRON | 7 |
| 9 | ONDANSETRON HYDROCHLORIDE | 7 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | PLATINUM | 3 | 0.0056 |
| 1 | NALDEMEDINE | 2 | 0.0012 |
| 2 | DUVELISIB | 1 | 0.0012 |
| 3 | DURVALUMAB | 19 | 0.0009 |
| 4 | IPILIMUMAB | 33 | 0.0008 |
| 5 | PEMETREXED DISODIUM | 29 | 0.0007 |
| 6 | NIVOLUMAB | 71 | 0.0007 |
| 7 | ANIDULAFUNGIN | 1 | 0.0006 |
| 8 | IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE | 1 | 0.0006 |
| 9 | MITOTANE | 1 | 0.0005 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Ligand-1 Blocker [EPC] | 19 | 0.0009 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 71 | 0.0007 |
| 2 | CTLA-4-directed Blocking Antibody [EPC] | 33 | 0.0007 |
| 3 | CD38-directed Cytolytic Antibody [EPC] | 2 | 0.0003 |
| 4 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 2 | 0.0003 |
| 5 | Blood Viscosity Reducer [EPC] | 1 | 0.0002 |
| 6 | Poly(ADP-Ribose) Polymerase Inhibitor [EPC] | 3 | 0.0001 |
| 7 | Platinum-based Drug [EPC] | 38 | 0.0001 |
| 8 | Phenothiazine [EPC] | 4 | 0.0001 |
| 9 | Echinocandin Antifungal [EPC] | 1 | 0.0001 |